Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris.
COVID-19
cancer
comorbidities
maintenance therapy
outpatients
pandemic
protocol adaptations
Journal
Clinical medicine (London, England)
ISSN: 1473-4893
Titre abrégé: Clin Med (Lond)
Pays: England
ID NLM: 101092853
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
pubmed:
4
8
2021
medline:
18
9
2021
entrez:
3
8
2021
Statut:
ppublish
Résumé
Cancer patients are a highly vulnerable group in the COVID-19 pandemic and it has been necessary for oncology units to adapt to this unexpected situation. We present our management of outpatients with cancer during the pandemic. We applied two major adaptations: extending the intervals between injections for maintenance therapy and protocol adaptation for patients with comorbidities. Between 17 March and 30 April 2020, 406 patients were treated in our outpatients department. Protocols were adapted for 94 (23.1%) patients. Among them, 49% had an extended interval between treatment administrations, 22.3% had modified protocols to reduce toxicity, 20.2% had therapeutic interruptions and 5.3% did not receive their treatment because of a COVID-19 infection. Overall, protocol adaptations concerned more than 20% of the patients. This pandemic was an opportunity for oncologists to re-examine the risk versus benefit balance of administering immunosuppressive treatment and highlighted that oncology daily routine should not be applied automatically.
Identifiants
pubmed: 34341004
pii: clinmed.2020-0666
doi: 10.7861/clinmed.2020-0666
pmc: PMC8439500
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e552-e555Informations de copyright
© Royal College of Physicians 2021. All rights reserved.
Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Lancet Oncol. 2020 May;21(5):634-636
pubmed: 32359487
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Lancet Oncol. 2020 May;21(5):619-621
pubmed: 32220659
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JCO Glob Oncol. 2020 Apr;6:557-559
pubmed: 32250659
Cancer Cell. 2020 Jun 8;37(6):742-745
pubmed: 32425702
JCO Oncol Pract. 2020 Jun;16(6):305-307
pubmed: 32324487